[1] Shipley JB, Hess ML. Inotropic therapy for the failing myocardium[J]. Clin Cardiol, 1995, 18(11): 615–619.
[2] Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults task force members[J]. JAC, 2009, 53(15): e1–e90.
[3] Belletti A, Castro ML, Silvetti S, et al. The effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials[J]. Br J Anaesth, 2015, 115(5): 656–675.
[4] Jaiswal A, Nguyen VQ, Le Jemtel TH, et al. Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure[J]. World J Cardiol, 2016, 8(7): 401–412.
[5] Tang X, Liu P, Li R, et al. Milrinone for the treatment of acute heart failure after acute myocardial infarction: a systematic review and meta-analysis[J]. Basic Clin Pharmacol Toxicol, 2015, 117(3): 186–194.
[6] Zangrillo A, Biondi-Zoccai G, Ponschab M, et al. Milrinone and mortality in adult cardiac surgery: a meta-analysis[J]. J Cardiothorac Vasc Anesth, 2012, 26(1): 70–77.
[7] Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure[J]. N Engl J Med, 1991, 325(21): 1468–1475.
[8] Chanani NK, Cowan DB, Takeuchi K, et al. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling[J]. Circulation, 2002, 106(12 Suppl 1): I284–I289.
[9] Liu H, Sangkum L, Liu G, et al. Effects of epinephrine on angiogenesis-related gene expressions in cultured rat cardiomyocytes[J]. J Biomed Res, 2016, 30(5): 380–385.
[10] Chen S, Liu GL, Li MM, et al. Effects of epinephrine on inflammation-related gene expressions in cultured rat cardiomyocytes[J]. Transl Perioper Pain Med, 2017, 2(1): 13–19.
[11] Zhao F, Li B, Wei YZ, et al. MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(6): 834–839.
[12] Merten KE, Jiang Y, Feng W, et al. Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway[J]. J Pharmacol Exp Ther, 2006, 319(2): 934–940.
[13] Hamid T, Xu Y, Ismahil MA, et al. TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate[J]. Am J PhysiolHear Circ Physiol, 2016, 311(5): H1189–H1201.
[14] Abu El-Asrar AM, Nawaz MI, Ola MS, et al. Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2013, 91(3): e169–e177.
[15] Hanatani S, Izumiya Y, Takashio S, et al. Circulating thrombospondin-2 reflects disease severity and predicts outcome of heart failure with reduced ejection fraction[J]. Circ J, 2014, 78(4): 903–910.
[16] Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts[J]. Circulation, 2005, 111(22): 2935–2942.
[17] Schroen B, Heymans S, Sharma U, et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy[J]. Circ Res, 2004, 95(5): 515–522.
[18] Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling[J]. Nat Rev Mol Cell Biol, 2007, 8(3): 221–233.
[19] Hori Y, Kashimoto T, Yonezawa T, et al. Matrix metalloproteinase-2 stimulates collagen-I expression through phosphorylation of focal adhesion kinase in rat cardiac fibroblasts[J]. Am J Physiol Cell Physiol, 2012, 303(9): C947–C953.
[20] Nepomnyashchikh LM, Lushnikova EL, Bakarev MA, et al. Immunohistochemical analysis of MMP-2 expression in the myocardium during the postinfarction period[J]. Bull Exp Biol Med, 2015, 159(4): 505–510.
[21] Gao L, Zheng YJ, Gu SS, et al. Degradation of cardiac myosin Milrinone alters inflammation-related gene expression 5light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion[J]. J Mol Cell Cardiol, 2014, 77: 102–112.
[22] Libby P. Collagenases and cracks in the plaque[J]. J Clin Invest, 2013, 123(8): 3201–3203.
[23] Newby AC. Metalloproteinase production from macrophages- a perfect storm leading to atherosclerotic plaque rupture and myocardial infarction[J]. Exp Physiol, 2016, 101(11): 1327–1337.
[24] Kostov K, Blazhev A, Atanasova M, et al. Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in prehypertensive and hypertensive patients with type 2 diabetes[J]. Int J Mol Sci, 2016, 17(8): 1–13.
[25] Jiang L, Zhang J, Monticone RE, et al. Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis[J]. Hypertension, 2012, 60(5): 1192–1199.
[26] Qian J, Chen Z, Lin J, et al. Decreased expression of CCAAT/ enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases[J]. Leuk Res, 2005, 29(12): 1435–1441.
[27] Lin J, Wang YL, Qian J, et al. Aberrant methylation of DNAdamage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome[J]. Leuk Res, 2010, 34(8): 991–994.
[28] Xu Y, Chen Z, Zhang G, et al. HSP90B1 overexpression predicts poor prognosis in NSCLC patients[J]. Tumour Biol, 2016, 37(10): 14321–14328.
[29] Shneyvays V, Zinman T, Shainberg A. Analysis of calcium responses mediated by the A3 adenosine receptor in cultured newborn rat cardiac myocytes[J]. Cell Calcium, 2004, 36(5): 387–396.
[30] Galal A, El-Bakly WM, Al Haleem EN, et al. Selective A3 adenosine receptor agonist protects against doxorubicininduced cardiotoxicity[J]. Cancer Chemother Pharmacol, 2016, 77(2): 309–322.
[31] Lu Z, Fassett J, Xu X, et al. Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure overloaded left ventricle[J]. Circulation, 2008, 118(17): 1713–1721.
[32] Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes[J]. Mol Metab, 2014, 3(4): 384–393.
[33] Meng C, Liu Z, Liu GL, et al. Ketamine promotes inflammation through increasing TLR4 expression in RAW264.7 cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(3): 419–425.
[34] Lund H, Boysen P, Åkesson CP, et al. Transient migration of large numbers of CD14(++) CD16(+) monocytes to the draining lymph node after onset of inflammation[J]. Front Immunol, 2016, 7: 322.
[35] Krasity BC, Troll JV, Lehnert EM, et al. Structural and functional features of a developmentally regulated lipopolysaccharide-binding protein[J]. MBio, 2015, 6(5): e01193–15.
[36] Friedrich K, Smit M, Brune M, et al. CD14 is associated with biliary stricture formation[J]. Hepatology, 2016, 64(3): 843–852.
[37] Guillou C, Fréret M, Fondard E, et al. Soluble alpha-enolase activates monocytes by CD14-dependent TLR4 signalling pathway and exhibits a dual function[J]. Sci Rep, 2016, 6: 23796.